User:Lnsampath7/sandbox

Shield Healthcare Is in Indian Pharmaceutical Company based in Chennai, founded in 1995, by L Mahadevan , a first generation entrepreneur.

History
Shield was promoted in the year 1995, as an ethical marketing company for pharmaceutical products, in India. The company started off with operations in Tamil Nadu and Kerala and gradually increased its foot prints to the states of Andhra Pradesh and Karnataka. As of June 2016, the operations of the company are present in over 14 states. The company is slated to have its presence across all states of India, by the turn of the financial year 2016-17.

Besides the promoter, who is a majority shareholder, Shield has a significant investment from Fulcrum Venture India, a private equity investor with a strong SME focus.

Company Details
Shield has a strong focus in the segment of women’s healthcare, specifically in Gynecology and Infertility space. Since inception Shield had been marketing formulations based on Health and Nutrition Supplements catering to diverse age groups. In the year 2011, Shield made a strategic decision to shift its focus and specialize in the segment that it calls “Menarche to Menopause”, with an objective to identify and market niche solutions for gynecological healthcare needs of women, in the stages between Menarche and Menopause.

Shield has a limited and focused portfolio comprising products that are either homegrown or solutions adopted from pharmaceutical product originators across the world. It collaborates with chosen companies involved in pharmaceutical research, to bring and market in India, healthcare solutions that are innovative and scientific.

Therapies and products
PCOD (PolyCystic Ovarian disorder): a common endocrine   disorder due to hormonal imbalance aggravated by metabolic impairment affecting 30 % of adult women. Shield’s product APCOD is among the top leaders in India in this segment as solution for Infertile Annovulatory PCOD. While APCOD has Myo-Inositol as its primary API, Shield markets APCOD OBIS, a differentiated product based on ‘Myo-Inositol & D Chiro Inositol’ for patients who are diagnosed with annovulatory PCOD coupled with the condition of obesity where the BMI of the patient is greater than 25. The product has significant usage in Infertility treatments as a PCOD is a strong precursor among women identified with fertility issues.

Infertility: Very often the condition requires Stimulation of the development of ovarian follicles and to trigger oocyte release from mature ovarian follicle to reverse anovulation or oligoovulation. . Shield’s product Ovaashield & Ovaashield DS helps in improving Ovulation Rate. The chances of conception are higher due to improvement in sperm mucus penetration. It also aids better implantation by improving endometrial thickness.

Gestational Diabetes Mellitus: It is a condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy (especially during third trimester) owing to factors such as human placental lactogen that interferes with susceptible insulin receptors. Shield’s product GDM Safe reduces insulin level, reduces fasting glucose levels and increases adiponectin level and effectively addresses insulin resistance. In high risk patients, GDM Safe when administered from first trimester the chances of GDM can be significantly reduced.

Post Partum Lochia & Dioxin-Free Menstrual Care: Lochia is the post-partum vaginal discharge (puerperium) with excessive bacterial colonization and delayed wound healing. Management of Lochia in Indian conditions are by using conventional sanitary napkins, where in the conventional sanitary napkins are made from wood and paper pulp with high dioxin content. Invariably the top sheets of the napkins are made from Rayon a non friendly material for the purpose. Shield’s products Lochia Pad and Jusmile are a dioxin-free, Non-rayon, non-bleached sanitary napkins giving protective care to women during Lochia and regular periods

Menopause: Conventional treatment options for menopausal symptoms have been identified to be both weak as well as risky. HRT (Hormone Replacement Therapies) have been found to result in high risk health conditions such as cancer, stroke, coronary diseases and Alzheimer’s. Treatment options using Phytoestrogens (Isoflovanoids) have been found to be ineffective due to weak estrogenic activity and poor effect in reducing bone loss. Estro G 100, innovated and patented by Naturalendo Tech, a South Korean Company and marketed in India by Shield, is a based on a proprietary blend of three native Korean herbs. The formulation regulates the estrogen affinity to ER in reproductive and Non Reproductive organs there by having a significant positive impact on clinical symptoms faced by Menopausal women.

Luteal Phase Support: Assisted Reproduction Technique (ART) is highly dependent on Luteal Phase support with Progesterone for their success. Conventional progesterone applications such as oral applications, gels, pessaries and others have been found to have critical shortcomings such as low bioavailability, poor endometrial concentration, severe physiological side effects as well as difficulty in practical usage. Shield’s product ART Luton is the first of its kind in India, where micronized Progesterone is administered in the vaginal route using a vaginal spray. The technology with very simple administering procedure is proving to be highly effective in improving endometrial concentration couple with very low side effects.

Financial Highlights
Shield Healthcare is a privately held company with a turnover of Rs 43.36 Crores (USD 6.7 Mn) for the year FY 2015-16 with a growth rate of 15.3% over the previous year. As per management reports, the company is expected to expand its operations across India in the year FY 2016-17. Its turnover is slated to grow at a CAGR of 35% between 2016-17 and 2020-21.